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A large majority of new chemical entities and many existing drug molecules exhibit poor aqueous 
solubility, which may limit their potential use in developing drug formulations, with optimum 
bioavailability. One of the approaches to improve the solubility of a poorly water soluble drug and 
eventually its bioavailability is complexation with agents like humic acid (HA), fulvic acid (FA), 
β-cyclodextrin (β-CD), 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and caffeine (Caff). The current 
work emphasized at employing these agents to prepare different complexes and their in vitro/in vivo 
assessment. All the complexes evaluated for their complexation efficiency and authenticated by molecular 
modeling; conformational analysis, differential scanning calorimetry (DSC), X-ray diffraction (XRD), 
nuclear magnetic resonance (NMR) and mass spectroscopy. Furthermore, the complexes were assessed 
in an in vivo, rat vaginal model for their efficacy in treatment of vaginal candidiasis. Amongst the five 
tested complexes, fulvic acid-itraconazole complex yielded better solubility as well as in vivo efficacy 
and therefore may further be explored for developing a commercial formulation for treating vaginal 
candidiasis.
Uniterms: Itraconazole/complexes/evaluation. Itraconazole/complexes/in vitro/in vivo performance. 
Vaginal candidiasis/treatment. Drugs/solubility. Drugs/formulation.
A maioria das novas entidades químicas e muitas moléculas de fármacos existentes apresenta fraca 
solubilidade em água, o que pode limitar seu uso potencial no desenvolvimento de formulações com 
biodisponibilidade ideal. Uma das abordagens para melhorar a solubilidade de um fármaco pouco solúvel 
em água e, eventualmente, a sua biodisponibilidade é a complexação com agentes como o ácido húmico 
(HA), ácido fúlvico (FA), β-ciclodextrina (β-CD), 2-hidroxipropil-β-ciclodextrina (HP-β-CD) e cafeína 
(Caff). O presente trabalho baseia-se no uso desses agentes para preparar diferentes complexos e suas 
avaliações in vitro/in vivo. Todos os complexos foram avaliados quanto à eficiência de complexação 
por modelação molecular, análise conformacional, calorimetria de varredura diferencial (DSC), difração 
de raios-X (XRD), ressonância magnética nuclear (RMN) e espectroscopia de massas. Além disso, os 
complexos foram avaliados in vivo, em ratas, no tocante à sua eficácia no tratamento de candidíase vaginal. 
Entre os cinco complexos testados, o complexo de ácido fúlvico-itraconazol foi o que apresentou melhor 
solubilidade, bem como melhor eficácia in vivo e, portanto, pode ser explorado para o desenvolvimento 
de uma formulação comercial para o tratamento de candidíase vaginal.
Unitermos: Itraconazol/complexos/avaliação. Itraconazol/complexos/desempenho in vitro/in vivo. 
Candidíase vaginal/tratamento. Fármacos/solubilidade. Fármacos/formulação.
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INTRODUCTION
It is estimated that nearly 40% of the newly de-
veloped drugs have an aqueous solubility of less than 
100 µg/mL (100 ppm) and some even lower than 
1 µg/mL (Prentis et al., 2003). This poor solubility be-
comes an impediment for the in vivo success of their for-
mulations as it limits the bioavailability of such drugs. An-
tifungals along with many other categories of newer drugs 
suffer from this problem. The approval of the triazoles in 
the early 1990s was a major progress in the ability to safely 
and effectively treat local and systemic fungal infections 
(Maertens, 2004). Itraconazole (Itz), a member of this class 
has attracted considerable attention for the treatment of 
wide range of fungal infections with considerably lower 
toxicity and a better therapeutic index when compared to 
Amphotericin B (Como, Dismukes,1994). However lim-
ited aqueous solubility and dissolution rate of Itz has been 
responsible for its poor absorption and consequently lower 
bioavailability (Bailey et al., 1990; Grant, Clissold, 1989). 
It is a weak basic drug, possessing extremely low water 
solubility (S~1 ng/ml at neutral pH). The calculated log P 
is 6.2 (Peeters et al., 2002) which indicate its high lipophi-
licity. Although Itz has elicited hydrophobic properties it 
is neither hydrophilic nor lipophilic at room temperature. 
Thus, it has always been a challenge to deliver this drug in 
a suitable dosage form. A technique that helped in bring-
ing this molecule into the market (Sporanox® by Jans-
sen Pharmaceuticals) was inclusion complexation with 
2-hydroxypropyl-β-cyclodextrin. Since the development 
of inclusion complexes of Itz has been well proven, this 
study explored the potential of various complexing agents 
from different sources to address the solubility problem 
of the molecule. Complexing agents (Figure 1) selected 
for the study were humic acid (HA), fulvic acid (FA), 
β-cyclodextrin (β-CD), 2-hydroxypropyl-β-cyclodextrin 
FIGURE 1- Molecular structure of itraconazole and different complexing agents (β- cyclodextrin, HP-β-cyclodextrin, caffeine, 
fulvic acid and humic acid)
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(HP- β-CD) and caffeine (Caff). Newly introduced humic 
acid and fulvic acid belong to natural organic matters, 
which form inclusion complexes with therapeutic mol-
ecules (Mirza et al., 2011). Cyclodextrins are torus-shaped 
oligosaccharides obtained from the enzymatic degradation 
of starch by bacteria (Szetjli, 1998) which readily form in-
clusion complexes with many lipophilic organic molecules 
both in solution and in the solid-state. Caffeine is a natural 
xanthine alkaloid compound that acts as a central nervous 
system stimulant and reportedly forms complexes by a 
charge transfer mechanism (Fouad et al., 2010). The study 
was aimed at identifying the best drug inclusion complex 
to be used in treatment of vaginal candidiasis.
MATERIAL AND METHODS
Material
Rock shilajit was obtained and authenticated from 
Dabur Research Foundation, Ghaziabad, India. Itracon-
azole was obtained as a gift sample from Jubilant Or-
ganosys, Noida, India. Chemicals and reagents used for 
the study were of analytical reagent grade and purchased 
from Merck India Ltd, Mumbai. Sporanox® (Johnson and 
Johnson) was purchased from local market. A slightly 
modified method (Mirza et al., 2010) was used to extract 
FA and HA from rock shilajit.
Methods
Equilibrium phase solubility studies
Phase solubility studies were carried out at room 
temperature (25 °C) in triplicate according to the method 
reported by Higuchi and Connors (Vlachou, Papaioan-
nou, 2003). Excess amount of drug was added to distilled 
water containing various concentrations (0.2- 2% w/v) 
of different complexing agents in a series of stoppered 
conical flask (100 mL) and shaken for 48 h on a mechani-
cal shaker. The suspensions were filtered through 0.45 
μm filter paper. The solubility and chemical stability of 
the drug was also assessed by a slight modification of a 
validated HPLC method (Yoo et al., 2000), with an accu-
racy of 95.5% and a precision of 6.7%. The analysis was 
carried out on a Waters Alliance e2695 separating module 
(Waters Co., MA, USA) using photo diode array detector 
(Waters 2998) with auto sampler and column oven. The 
instrument was controlled by use of Empower software 
installed with the equipment for data collection and ac-
quisition. Compounds were separated using a C18 reverse 
phase column (25 x 4.6 mm, particle size 5 µm, Merck, 
Germany) maintained at room temperature. The mobile 
phase consisted of acetonitrile, 0.05% diethylamine in 
deionized water (7:3, v/v), with the pH adjusted to 7.0 by 
drop wise addition of phosphoric acid. The flow rate was 
1 mL/min and the detection wavelength was set at 260 nm. 
10 μL of the sample was injected into the column. Rt of Itz 
was observed at 8.25 min.
Preparation of complexes by Freeze drying method
The required stoichiometric (1:1, 1:2 and 1:3) 
quantity of drug was added to an aqueous solution of the 
complexing agent and was agitated on a magnetic stirrer 
for 24 h. Sucrose solution (2%, w/v) was added as a cryo-
protectant. The resulting solutions were frozen at (-70 oC) 
in a deep freezer for overnight. This was then lyophilized 
(Dry Winner, DW-8-85 Heto Holten, Denmark) to obtain 
a dried mass which was further powdered in a glass mortar 
and pestle and passed through a 100-mesh sieve to obtain 
a uniform-size fine powder. The samples were then trans-
ferred into vacuum desiccators and dried over silica gel 
under vacuum for at least 24 h. A similar batch of complex, 
without cryoprotectant was also developed to carry out 
instrumental analysis like DSC and XRD.
Characterization of complexes
·	 Differential scanning calorimetry
DSC thermograms were obtained under a nitrogen 
gas flow of 50 ml/min. Calibration of the DSC instrument 
(DSC-7, Perkin Elmer Pyris 6 instrument, USA) was car-
ried out using indium as standard. Sample powders (5 mg) 
were crimped in an aluminum pan and heated at a rate of 
10 K. min−1. Generally, scan rates were taken between 1 
and 10 K. min−1. Low scan rates are preferable in terms 
of peak resolution and investigation of the sample having 
close peaks while high scan rates increase the sensitivity 
of the measurement as they lead to the exchange of heat 
within a comparatively short time period. Further, scan 
rate may also influence the course of temperature related 
processes within the sample. Samples were heated from 30 
to 350 °C (highest melting points of organic substances).
·	 X ray diffraction
XRD samples were studied using X-ray diffractom-
eter (PW 1830, Phillips, Banglore, Karnataka, India). The 
samples (1000 mg) on XRD plates were rotated during 
data collection to reduce orientation effects of particles. 
XRD patterns of all the samples were recorded between 
2θ = 5° and 70° at 35 kV and 30 mA, respectively.
·	 Proton nuclear magnetic resonance (1H NMR)
Proton Magnetic Resonance (1H NMR) spectra were 
recorded on Brucker Model DRX-300 NMR spectrometer 
in CDCl3 using tetramethylsilane (TMS) as the internal 
standard. Chemical shifts are reported in parts per million 
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(ppm, δ) and signals are described as singlet (s), doublet 
(d), triplet (t), quartet (q) and multiplet (m).
·	 Mass spectroscopy
Mass spectroscopy was carried out only for Itz- FA 
complexes. Samples were taken from the linear regions 
of phase solubility study to evaluate the complexation. 
The samples were dissolved in Milli-Q water to make a 
stock solution of 1 mg/mL and then further dilution was 
prepared in Milli-Q water: Methanol (50:50). Finally a 
concentration of 100 ng/mL was prepared and injected 
into the mass spectrometer (Synapt Mass Spectrometry, 
Q-TOF with UPLC) on electrospray ionization with 
positive mode. Capillary, sampling cone, and extrac-
tion voltages were 2.51, 21 and 5.3 units respectively. 
Source and desolvation temperatures were 80 °C and 
250 °C, respectively. Nitrogen gas was used as cone and 
desolvation gas at 50 and 600 L/h respectively, while trap 
collision energy of 6.0 units was used. The system was 
from Waters bearing serial No. JAA 272, USA. Software 
used was MassLynx V 4.1.
·	 Determination of complexation efficiency
The ability of complexing agents to complex Itz 
was determined quantitatively by UV spectrophotometer 
(Hassan et al., 2007). Acetonitrile was used for the de-
termination of free Itz content since complexing agents 
taken, had poor solubility in acetonitrile and the inclusion 
complex was also expected to have low solubility in ace-
tonitrile. To estimate free Itz content, 10 mg of the sample 
was dissolved in 100 ml of acetonitrile. This solution was 
then sonicated for 2 min, filtered on a 0.45 µm filter (Mil-
lipore) and analyzed using UV spectroscopy (UV 1601, 
Shimadzu, Japan) at 260 nm. The free Itz content was 
determined in triplicate. Following equation was used to 
determine the complexation efficiency,
Saturation solubility of complexes at vaginal pH
Excess amount of different complexes were added to 
10 ml of an aqueous solution (pH 4.5). They were shaken 
in a water bath (Ray Scientifics Instruments, India) for 5 
days at 37 °C, centrifuged (Tomy MX-305, Japan) at 3000 
rpm for 10 min and filtered using 0.45 µm filter paper. 
The concentration of Itz in the resulting solutions was 
then analyzed by the method described in earlier section. 
The resulting values were the average of at least three 
replicates.
The standard solution Gibbs energies were calcu-
lated using following equation: 
ΔGosol = −RT ln X2
where; X2 is the molar fraction of Itz in a saturated solu-
tion.
The standard solution enthalpies (ΔHo) were derived 
from temperature dependencies of drug solubilities ex-
pressed in molar fractions (van’t Hoff equation):
D lnX2/dT = ΔHo sol/RT2
For use of the above equation following assumptions 
were made: (a) the activity coefficients of dissolved drugs 
do not deviate from unity and (b) the solution enthalpies do 
not depend on concentration. The solution heat capacities 
are considered to be constant within studied temperature 
range, since the temperature dependence of solubility is 
described by linear equations.
Determination of driving force of solubilisation 
To determine the driving force for solubilisation 
of the bulk drug and complexes among different ther-
modynamic parameters (Gibb’s free energy, entropy and 
enthalpy), the following study was carried out. Different 
aqueous solutions with variable pH (1 and 4) were pre-
pared by the dropwise addition of conc. HCl into 100 ml 
of Milli Q water and the required pH was confirmed using 
a pH meter (Decibel 1011, Chandigarh, India). Excess of 
each sample was added to different pH solutions and the 
solubility was determined by the method described in ear-
lier section. Here aqueous solutions of variable pH were 
selected instead of buffer solution as in an earlier study 
(Perlovich et al., 2003) composition of buffer was found 
to have pronounced effect in determining the thermody-
namic driving force for solubility enhancement during the 
complexation studies.
In vitro release study
Drug release study of active pharmaceutical ingre-
dient (100 mg Itz suspension) and inclusion complexes 
(equivalent to 100 mg Itz) was performed using USP II 
dissolution apparatus (Hanson Research SRS, Chatsworth, 
CA, USA) in 900 ml of simulated vaginal fluid (Owen, 
1995) containing 1% sodium lauryl sulphate at 50 rpm and 
37 oC±0.5 oC. The study was carried out by transferring the 
constituted suspension (5 mL) in dialysis bag (Spectra-Por 
dialysis bag (Sigma Aldrich, St. Louis, MO, USA) with 
cutoff 12,000–14,000 Da). The concentration of Itz was 
determined using HPLC method described earlier. All dis-
solution studies were carried out in triplicate.
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In vitro antifungal studies
In vitro antifungal studies were performed against 
clinical isolates of Candida albicans in Sabouraud’s agar 
medium by the cup plate method. The marketed formula-
tion (Sporanox 100 mg Capsule) was suspended in 2 mL of 
sterilized water and transferred into the well of agar plate. 
Suspension of complexes equivalent to 100 mg of Itz was 
also prepared in the same manner. 2 ml of distilled water 
was used as the control. All the samples were applied in 
triplicate. Covered petridishes were incubated at 32 °C in 
the BOD incubator (LHC-78-Labhospmake, India) for 40 
h. The zone of inhibition was measured at the end of 40 h.
In vivo antifungal studies
The in vivo studies in a rat infection model were car-
ried out in order to assess the efficacy of different complexes 
(De Bernardis et al., 1997). The animal study protocol was 
duly approved by the Institutional Animal Ethical Commit-
tee of Jamia Hamdard (proposal number 742). Twenty four 
female wistar rats were divided in groups of four for the 
application of Itz-Caff, Itz-FA, Itz- HP-β-C D complexes 
while one group was taken as a control. All the complexes 
were formulated as 2% w/w thermosensitive gels to ensure 
an easy application onto the vaginal tissue. An earlier study 
had reportedly (Francois, 2003) used 5 g of 2% Itz cream 
which was well tolerated and not absorbed systemically 
and hence it is expected that 2% w/w Itz would not be 
absorbed systemically in the experimental rat model. Gel 
was prepared according to the cold method (Choi et al., 
1998). Briefly, mucoadhesive polymer (Carbopol 934) 
(0.2% w/v) was slowly added to citrate phosphate buffer 
(0.1 M, pH 4.0) at 4 oC with gentle mixing for an hour and 
allowed to hydrate. Then it was centrifuged at 3000 rpm for 
15 min to remove the air bubbles. Care was taken to allow 
the minimum air bubbles level during handling. Pluronic® 
F 127 (18% w/v) was then added to CP 934 solution and 
allowed to dissolve overnight at 4 oC. Calculated amount 
of complexes were then added in a solution form and total 
volume was adjusted. Six days prior to the inoculation of 
infection, all animals were maintained under pseudoestrus 
stage by subcutaneous administration of estradiol benzo-
ate. Into these oophorectomized rats C. albicans (108 cells 
per ml of saline) were inoculated. Then different gels laden 
with different drug- inclusion complexes (1 g) were applied. 
Control constituted of plain placebo gel. During specified 
time intervals 1 µL of the fluid from vaginal cavity was 
withdrawn, diluted and spread on Sabouraud agar contain-
ing chloramphenicol (50 mg/mL). It was then incubated at 
32 °C in the BOD incubator (LHC-78-Labhospmake, India) 
for 48 h and CFUs were counted. A rat was considered 
infected when at least 1 CFU was present in the vaginal 
sample (i.e., a count of ≥103 CFU/mL). A graph was plotted 
between time (days) and number of CFUs present in vaginal 
fluid and different complexes studied comparatively. 
In vitro cell toxicity studies
An MTT assay was used to assess the cytotoxicity 
of the free drug as well as the control and the complexes. 
The MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetra-
zolium bromide) assay is based on conversion of yellow 
water soluble tetrazolium dye to a water-insoluble purple 
formazan by living cells. The amount of formazan gener-
ated is directly proportional to the number of viable cells.
MCF-7 cells (ATCC, USA grown in NII, New Delhi) 
were grown (37 oC, 5% CO2 in water jacketed incubator 
shell) using DMEM media (Dulbeccos modified agar 
medium for cell culture growth, Gibco Invitrogen, USA) 
with 10% FBS and seeded on a single 96 well plate (Corn-
ing costar, USA) and allowed to adhere for MTT assays. 
Following this a concentration of free drug as well as the 
control and complexes ranging from 50 µg/mL to 500 
µg/mL having equivalent concentration were added in 
duplicates to the single 96 well tissue culture plate (Falcon 
Plate, Corning costar, USA). After 24 hours of treatment, 
the MTT assay was performed to check cell viability (Mos-
mann, 1983). For the MTT assay, the media was removed 
from all the wells, 10 µL of MTT reagent (Chemicon 
International, USA) per well from a working stock (5 mg/
mL) was added and the plates incubated (37 oC and 5% 
CO2) for 2-3 h, after that the reagent was removed and the 
crystals were solubilised using isopropyl alcohol (IPA). 
This IPA extract (Isopropanol with 0.1 N HCl) was then 
transferred to 96 well-plates. The HCl converts the phenol 
red in the tissue culture medium to a yellow colour that 
does not interfere with the MTT formazan measurement. 
The Isopropanol dissolves the formazan to give a homo-
geneous blue solution. The absorbance was measured at 
a test wavelength of 570 nm and reference wavelength of 
630 nm using an ELISA plate reader, LMR-340 M (La-
bexim International, Austria). The value of absorbance is 
considered to be the measure of the number of live cells.
RESULTS AND DISCUSSION
Phase solubility studies
Phase solubility analyses of Itz in presence of dif-
ferent complexing agents are given in Figure 2. Here 
different natures of interactions between complexing 
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agents and Itz have been observed. Broadly, two types of 
interactions were observed. In one category curve fitting 
line was inclined towards Y-axis while in other category, 
it was inclined towards X-axis. This tendency may be used 
to predict the comparative orders of complexation. With 
respect to complexing agents, HA and FA were exhibiting 
lower order of complexation as compared to HP-β-CD, 
CD and Caffeine. The total solubility (STotal) of a drug as a 
function of concentration of different complexing agents 
is given by any of the following equations which also 
give an estimate to predict the stoichiometric ratios of 
complexation. For single order complexation, solubility 
relationship is expressed by:
STotal = S0 + m [DmCA]
where, S0 is the drug concentration in the absence 
of complexing agents and m refers to the stoichiometry of 
the complexation. Here, one molecule of the drug interacts 
with one molecule of complexing agents. Thus, solubility 
of Itz can be assumed linear and proportional with com-
plexing agent when stoichiometry of complexation is 1. 
This is the case with HA and FA. For second order com-
plexation (one drug molecule interacts with two molecules 
of complexing agents), fitting the data to a quadratic model 
is appropriate. It is expressed by:
STotal = S0 + K1:1S0 [CA] + K1:1K1:2S0 [CA] 2
A positive deviation from the linearity for the 
phase-solubility diagram and deconvolution of the curve 
is observed with higher order complexes. In third order 
complexation, one molecule of the drug interacts with 
three molecules of complexing agents. To account for 
the concentration of complexing agents in these cubic 
relationships (Peeters et al., 2002) suggested a non-linear 
optimization technique based on Nelder-Mead approach. 
Higher ordered complexation is observed with remaining 
complexing agents. So, cyclodextrin molecules (β-CD 
and HP-β-CD) are considered to interact in a fashion 
of second order. On the other hand caffeine molecule 
follows a third order pattern which is also evident from 
the literature.
A phase solubility graph is also used to determine the 
binding constant and other thermodynamic (ΔG, ΔH and 
ΔS) parameters (Yadav et al., 2009). The binding constant 
was calculated according to the formula:
where, S0 is the solubility of Itz without complexing 
agents.
FIGURE 2- Phase solubility studies of Itraconazole at room temperature (25 °C). Curve fitting line appears to be divided into two 
groups.
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TABLE I - Saturation solubility of complexes at vaginal pH 4
Substances Solubility (µg/ml) at pH 4
X2 
(molar fraction)
ΔG298sol 
(kJ mol−1)
ΔH298sol 
(kJ mol−1)
T ΔS298 sol 
(kJ mol−1)
ΔS298sol 
(J mol−1 K−1)
1:1 Itz-FA 5.81±1.4 0.149×10-6 38.94 48.3±0.5 9.36 31.4
1:1 Itz- HA 3.11±0.3 0.08×10-6 40.47 52.1± 0.5 11.63 39.02
1:2 Itz- HP-β-CD 0.221±0.02 0.005×10-6 47.34 47.2±0.7 -0.14 -0.469
1:2 Itz- β-CD 0.179±0.004 0.0046×10-6 47.55 46±0.9 -1.55 -5.20
1:3 Itz- Caff 0.156±0.023 0.00402×10-6 47.88 46.1±1.1 -1.78 -5.97
Itz 0.13±3.7 0.0033×10-6 48.46 44.5±0.8 -3.96 -13.28
The binding constant for different complexes was 
found to be varying like Itz-FA (1104.26 M-1), Itz-HA 
(1024.65 M-1), Itz-HP-β-CD (1012.44 M-1), Itz- β-CD 
(993.47 M-1) and Itz- Caffeine (568.21 M-1). Stability 
constant (Ks) values lying between 200 and 5,000 M−1 are 
considered as most suitable for the improvement of solu-
bility and stability of a poorly soluble drug (Patel, Patel; 
2007). To investigate the spontaneity and feasibility of the 
entrapment by the thermodynamic approach, changes in 
Gibb’s free energy (ΔG) were also calculated (at constant 
temperature and pressure). It is the net energy available 
for useful work.
ΔGosol = −RT ln X2
Where, X2 is the molar fraction of Itz in a saturated 
solution. Results obtained are given in Table I. Other ther-
modynamic parameters are obtained by using Van’t Hoff 
equation. Ks are calculated at different temperatures and 
ΔH is calculated according to the equation given below;
or,
Thus, if a plot is drawn between 1/T and Log K, 
slope of the plot will be ΔH. Entropy may be calculated 
using the equation:
ΔG = ΔH - T ΔS
Characterization of complexes
Differential scanning calorimetry
DSC is a tool to investigate the melting and re-
crystallization behavior of crystalline materials. Organic 
substances usually show a melting range. An increased 
melting range could be correlated with impurities or less 
ordered crystals. The DSC analysis showed a sharp peak of 
Itz at 170 oC. None of the complexing agents showed any 
sharp peak except Caffeine at 192 oC. All the complexes 
exhibited broad humps at variable temperature ranges 
(Figure 3). It may be inferred from the thermograms that 
Itz may have lost its crystalline pattern and thus is present 
in its amorphous form. The details from the thermograms 
of Itz and its complexes are given in Table II.
Melting enthalpy (ΔH), expressed in joule/gram 
(J/g) is a characteristic of the crystal order if the influ-
ence of impurities can be ignored. For the less ordered 
crystal or amorphous state, the melting of the substance 
requires less energy than the perfect crystalline substance 
which is required to overcome the lattice energy. As a 
result, the higher melting enthalpy values should sug-
gest higher ordered lattice arrangement and vice versa. 
The higher enthalpies were noted with single entities 
TABLE II - DSC of pure Itraconazole, complexing agents and 
complexes
Samples ΔH (j/g) Maximum 
peak (°C)
Peak width
Itz 105.035 170.408 6.62
FA 142.075 162.387 11.13
Itz-FA 78.502 136.214 26.44
HA 44.236 77.365 44.63
Itz-HA 31.461 163.628 16.50
HP-β-CD 33.768 119.876 31.42
Itz- HP-β-CD 69.119 161.452 11.22
β-CD 117.96 127.625 41.26
Itz- β-CD 49.825 147.473 8.32
Caffeine 124.630 198.524 7.46
Itz- Caff 69.215 81.213 4.29
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like Itz (105.035 j/g), FA (142.075 j/g), β-CD (117.96 
j/g) and caffeine (124.630 j/g). So far the complexes are 
concerned, ΔH values were comparatively lower. Thus, it 
may be inferred from the results that complexes have more 
disordered structures. This decrease in disorder is created 
due to positive interaction between two entities (drug and 
complexing agents).
Peak width is another parameter to study but it de-
pends largely upon particle size especially in nanometric 
range as explained by Gibbs–Thomson equation:
Ln T/T0 = 2gslVs/rDHfus
where, T - Melting temperature of a particle with radius r; 
T0 - Melting temperature of the bulk material at the same 
external pressure; γsl - Interfacial tension at the solid-liquid 
interface; VS - Specific volume of the solid; ΔHfus - Specific 
heat of fusion
Peak width is actually an integration of peaks of dif-
ferent size ranges. When the particle size distribution is 
wide spread, it is higher and vice versa. The particle size 
of unprocessed drug is around 152.3 nm with a PDI of 
0.8. Other samples were passed through sieve 100 hence 
a higher size distribution could be expected.
Although DSC is able to monitor and quantify even 
minute thermal events in the sample (depending on the 
sensitivity of the instrument) and to identify the tempera-
tures at which these events occur. But it does not directly 
reveal the cause of a thermal event. The exact nature of 
the thermal transitions has to be determined with other 
complementary methods such as microscopic observa-
tions, X-ray diffraction or spectroscopic techniques to 
distinguish, for example, between melting, polymorphic 
transitions, loss of water from hydrates or decomposition 
of the substance.
X-ray diffraction
Use of these two techniques (DSC and XRD) often 
lead to complementary information on the systems of 
interest and data evaluation from these methods is usu-
ally straight forward. Such a plot (2θ Vs % Intensity) can 
be considered a fingerprint of the crystal structure and 
to differentiate with different crystallographic status of 
the system. One peak will be exhibited for all repeating 
planes with the same spacing. By contrast, an amorphous 
sample will exhibit a broad hump in the pattern called 
an amorphous halo. These patterns are representative 
of the structure but do not give positional information 
about the atoms in the molecule. Itz was showing a 
characteristic crystalline pattern (Figure 4) exhibiting 
intense peaks at 20.38 (100%), 20.40 (97.59%), 20.36 
(96.53%), 20.34 (88.53%), 20.32 (80.66%) and 17.5 
(77.9%) etc. Few sharp peaks were present only in caf-
feine (100% at 11.24, 49.56% at 27.32, and 47.64% at 
28.42) and HP-β-CD (100% at 12.34, 39.40% at 23.68, 
42.52% at 25.34 etc). Other complexing agents (FA, HA 
and β-CD) were almost amorphous in nature (Figure 5). 
XRD of Itz-HA and Itz-FA showed amorphous nature 
and some diminished peaks were observed in Itz-HP-β-
CD, Itz-β-CD and Itz- Caffeine complexes (Figure 4). 
These peaks were not from the fingerprint regions of Itz 
but from the complexing agents themselves. Thus, the 
XRD of inclusion complexes showed their amorphous 
nature, indicating entrapment of drug and, peaks if any 
were appreciably diminished.
Proton nuclear magnetic resonance (1H NMR)
The 1H NMR spectra of Itz (Figure 6) showed 
singlet protons at δ 8.29 and 8.37 for triazoles nucleus. 
While 1H NMR spectra of Itz-β-CD complex showed 
two singlet peaks at δ 8.31 and 8.39 which are slighlty 
downfield shifted peaks. All the other peaks of both β-CD 
and Itz remain almost unchanged. This clearly indicates 
the inclusion phenomena of the triazoles nucleus into 
the β-CD cavity (Spulber et al., 2008). Nearly same 
phenomena was observed for inclusion complex of Itz 
with FA, HA and HP- β-CD. The downfield shift values 
observed were δ 8.32 and 8.44 for Itz-FA, δ 8.34 and 8.42 
FIGURE 3- Representative DSC profiles of itraconazole, 
complexing agents and different complexes.
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FIGURE 4- X-ray powder diffraction of itraconazole and 
complexes.
FIGURE 5- X-ray powder diffraction of complexing agents.
for Itz-HA, δ 8.30 and 8.40 for Itz- HP- β-CD. 1H NMR 
spectra of Itz-caffeine complex also showed changes 
in both the protons and shifting pattern of the proton in 
Itz-and caffeine. H8 proton of caffeine was observed at 
δ 7.90 where as Itz-caffeine complex showed H8 peak as 
upfolded doublet at δ 7.84. Also triazole nucleus of Itz 
showed one singlet at δ 8.28 and doublet at δ 8.34. This 
clearly indicates the introduction of H8 (caffeine) with 
H3 of triazole.
Mass spectroscopy
The various studies had elicited that fulvic acid was 
a better complexing agent hence; mass study was carried 
only for this. A representative spectrum is given in Figure 
7. In all the mass spectra some peaks were common (with 
m/z variation ~ 5) that were either non-complexed drug 
(Itz), non-complexed fulvic acid (avg. molecular wt ~ 
1200) or 1:1 and 1:2 complexes. Extensive noise was also 
present. It was evident from the result that in any complex 
(irrespective of the ratio) some fraction of uncomplexed 
drug, uncomplexed fulvic acid and 1:2/ 1:1 complexes 
were present. Their relative abundances depended upon 
the ratio (1:1 or 1:2) taken.
Determination of complexation efficiency
The results obtained for complexation efficiency 
studies are given in Table III. All the complexes showed 
appropriate acceptability except Itz-Caffeine complex (~ 
47.54). In author’s point of view this may not be a very ap-
propriate method to determine the complexation efficiency 
as high sonication energy may result into dissociation of 
no bond complexes (inclusion complex). However, due to 
unavailability of any appropriate method, authors had to 
follow the reported method.
FIGURE 6- NMR spectra of itraconazole.
TABLE III - Complexation efficiencies of different complexes
Samples % Complexation efficiency ±SD (n=3)
1:1 FA-Itz 67.32±2.6
1:1 HA-Itz 59.21±1.9
1:2 Itz- HP-β-CD 61.48±3.3
1:2 Itz- β-CD 58.31±1.4
1:3 Itz- Caff 47.54±2.7
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Saturation solubility of complexes at vaginal pH
The study was conducted for over a period of five 
days which yielded saturated samples. The maximum 
solubility was observed with 1:1 Itz-FA complex (5.81±1.4 
µg/mL). Decreasing order of solubility is given in Table I. 
Thermodynamic parameters (ΔG, ΔH and ΔS) calculated 
for the samples are also given in the same table. Positive 
signs of enthalpy of solublisation (ΔH) indicate that it is 
an endothermic process at room temperature and crystal 
lattice energy of the substance outweighs the solvation 
energy. Positive values of ΔG also indicate that the process 
is non-spontaneous at room temperature and is driven by 
some energy source. Nature of change of disorder (ΔS) is 
different in all systems (complexes). In case of HA and 
FA complexes, it is increasing (positive values) while in 
other cases (HP-β-CD, β-CD and Caffeine) it is decreasing 
(negative values). With increasing disorder of the system, 
we may expect better encapsulation of one moiety into 
another.
Determination of driving force of solubilization
Thermodynamic parameters calculated for different 
samples presented a clear picture about the driving forces 
involved when the pH is varied in acidic range (4 to 1). 
Vaginal milieu is acidic at normal physiological conditions 
but often rises to alkaline during infections. Marketed for-
mulations like Aci-gel, Buffer gels etc are often prescribed 
to maintain vaginal acidity which eventually curtails the 
vaginal floral growth. Conclusively, there is a significant 
pH variation in the vaginal cavity. Itz also elicits variation 
in ionic state at different pH which translates into differen-
tial interaction with the complexing agents. Itz is a weak 
base with four ionizable nitrogen atoms. The two pKa 
values are 4 and 1.5–2 whereas the other ionizable nitro-
gen is not protonated between pH 2 and 10 (Peeters et al., 
2002). Also the pKa of the nitrogen atom of the triazolone 
moiety is 4.0. This explains the sudden drop in solubility 
above pH 3 and the associated changes in both solubility 
and dissolution. It also explains non linear (ascending or 
descending) pattern for any thermodynamic parameter 
during complexation. The sudden drop in solubility of Itz 
above pH 3 leads to a greater hydrophobic interaction of 
guest and host molecules and the Itz penetrates deep into 
the host molecule thus creating Van der Waals interaction 
and hydrogen bonds thereafter. For the complexes and API 
the values of ΔG and ΔH are positive (ΔS were found to 
be both positive and negative). Thus we can conclude that 
complexation of Itz with fulvic acid is non-spontaneous at 
low temperature while spontaneous at high temperature. 
Here, terms low temperature and high temperatures are 
relative terms. For a particular reaction, high temperature 
could mean room temperature also.
FIGURE 7- Mass spectra of Itz-FA complex. Peaks of uncomplexed drug, uncomplexed FA and different molar ratios are evident 
in the spectra obtained.
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TABLE IV - Thermodynamic parameters of solubilisation process of pure Itraconazole, 1:1 FA-Itz and 1:1 HA-Itz, 1:2 Itz- HP-β-
CD, 1:2 Itz- β-CD and 1:3 Itz-Caff complexes in aqueous solution at variable pH at 298 K
Samples pH Solubility (µg/ ml)
X2 (molar 
fraction)
ΔG298sol 
(kJ mol−1)
ΔH298sol 
(kJ mol−1)
T. ΔS298 sol 
(kJ mol−1)
ΔS298sol 
(J mol−1 K−1) εS
a [%]
API (Itz) 1 24.17±2.3 0.618× 10-6 35.42 55.3±0.71 19.88 66.71 56.12
4 0.13±3.7 0.0033× 10-6 48.46 44.5±0.8 -3.96 -13.28 -8.17
1:1 FA-Itz 1 78.46±2.6 2.02×10-6 32.48 38.3±0.6 5.82 19.5 17.91
4 5.81±1.4 0.149×10-6 38.94 48.3±0.5 9.4 31.4 24.13
1:1 HA-Itz 1  33.26±1.3 0.857×10-6 34.60 58.1±1.8 23.5 78.85 67.91
4 3.11±0.3 0.08×10-6 40.47 52.1± 0.5 11.63 39.02 28.73
1:2 Itz- HP-β-CD 1  92.56 ±1.7 2.38×10-6 32.07 42.3±0.7 10.23 34.32 31.89
4 0.221±0.02 0.005×10-6 47.34 47.2±0.7 -0.14 -0.47 -0.29
1:2 Itz- β-CD 1  83.17 ±3.2 2.14×10-6 32.33 40.6±0.4 8.27 27.75 25.57
4 0.179±0.004 0.0046×10-6 47.55 46±0.9 -1.55 -5.2 -3.25
1:3 Itz- Caff 1  56.48 ±2.4 1.46×10-6 33.28 48.5±0.8 15.22 51.07 45.77
4 0.156±0.023 0.00402×10-6 47.88 46.1±1.1 -1.78 -5.97 -3.71
aεS = [(T.ΔS°) / ΔG°].100
TABLE V - Release kinetics and mechanism involved with different complexes
Formulations
Zero-order First-order Higuchi matrix Korsmeyer-peppas
Best fit model
r2 r2 r2 r2 Rel. Expo. (n)
1:1 Itz-FA 0.967 0.995 0.974 0.960 0.326 First order
1:1 Itz- HA 0.967 0.982 0.932 0.960 0.319 First order
1:2 Itz- HP-β-CD 0.967 0.988 0.963 0.960 0.326 First order
1:2 Itz- β-CD 0.967 0.968 0.946 0.960 0.326 First order
1:3 Itz- Caff 0.967 0.996 0.990 0.960 0.326 First order
Change in entropy (as the pH of the solution was 
moved from 4 to 1) was observed to be the main driving 
force as it increased substantially. Although it was nega-
tive also in case of 1:1 Itz-FA, but other factors (ΔG and 
ΔH) were more negative as compared to ΔS (Table IV). 
At pH 1, Itz molecule has a solvation shell, which consists 
of entropically ordered molecules of the medium in the 
space next to the ionized atoms, and a more disordered 
part of the solvation shell is located around other parts 
of the molecule (hydrophobic effect). Thus during com-
plexation the ordered shell portion along with some other 
hydrophobic portions finds its way into the cavity leaving 
behind disordered portions.
In vitro release studies
The results obtained after dissolution study are given 
in Figure 8. To analyze the in vitro release data various 
kinetic models were used to describe the release kinetics. 
The zero order rates describe the systems where the drug 
release rate is independent of its concentration. The first 
order describes the release from system where release 
rate is concentration dependent (order is one). Higuchi 
described the release of drugs from insoluble matrix as a 
square root of time dependent process based on Fickian 
diffusion. Whereas, Peppas Korsemeyer describes the log 
fraction of drug release with respect to log time. Release 
order of all the complexes appears to be first order (Table 
V). To evaluate the mechanism of drug release from the 
preparation, data of drug release may be plotted in Kors-
meyer and Peppas equation (Korsmeyer et al., 1983):
Log (Mt/Mf) = LogK + n log t
It is often used to describe the drug release behavior 
from polymeric systems. Where Mt is the amount of drug 
release at time t, Mf is the amount of drug release after 
infinite time; k is release rate constant incorporating struc-
tural and geometric characteristics of the dosage form, n 
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is the diffusional exponent indicative of the mechanism 
of drug release. The log value of percent drug dissolved 
is plotted against log time for each formulation according 
to the equation. For a cylinder shaped matrix the value of 
n ≤ 0.45 indicates Fickian release; > 0.45 but < 0.89 for 
non-Fickian (anomalous) release; and > 0.89 indicates 
super diffusion type of release. It generally refers to the 
erosion of the polymeric chain and anomalous transport 
(Non-Fickian) refers to a combination of both diffusion 
and erosion controlled drug release. In all five complexes 
release appears to be Fickian diffusion (n ≤ 0.326).
In Vitro antifungal studies
All the wells except those containing control (dis-
tilled water) produced an appreciably larger zone of inhi-
bition than Itz alone. Smallest zone produced by pure Itz 
may be due to minimal solubility of the drug in an aqueous 
media. Sporanax and 1:2 Itz-HP-β-CD produced almost 
similar zones as the same excipient is used in both. Among 
all complexes 1:3 Itz-Caff produced smallest zone. It is 
quite evident from earlier data that caffeine complexes 
were showing minimal solubility. Since, the size of zone 
largely depends upon the solubility and diffusibility of 
the sample through the agar media hence the results are 
inferred with this perspective (Table VI).
In vivo antifungal studies
Three complexes (Itz-Caff, Itz-FA and Itz-HP-β-CD) 
whose performances were better in release studies and in 
vitro antifungal studies were submitted for in vivo infection 
model studies (Figure 9). Control was not having any drug 
but little improvement in infection was observed which may 
be due to conditioning effect of carbopol 934. Highest ame-
FIGURE 8 - In vitro drug release profile of complexes. Maximum 
drug release was observed with Itz-Caff complexes. While 
minimum was observed with Itz-HA complexes. Thus later 
appears to have a more sustained release profile.
TABLE VI - In vitro anti fungal activity of different complexes 
by cup-plate method
Substances Zone of inhibition (n=3) in cm
Distilled water --
Sporanax 100 mg Capsule 1.6 ± 0.3
100 mg Itz 0.4 ± 0.2
1:1 Itz-FA 1.5 ± 0.4
1:1 Itz-HA 1.1 ± 0.2
1:2 Itz- HP-β-CD 1.7±0.2
1:2 Itz- β-CD 1.4±0.3
1:3 Itz- Caff 0.9±0.2
lioration was effected by Itz-FA. But unexpectedly, Itz-Caff 
performed better than Itz-HP-β-CD which was not evident 
in vitro antifungal studies. As per the authors’ inferences, 
it may be due to two factors favoring caffeine complexes. 
Although similar solubility profile was obtained in case 
of both the complexes but a non-concentration gradient 
mechanism of drug release is involved in case of caffeine. 
Moreover, caffeine and Itz are bound together by charge 
transfer mechanism and this complex may de-stabilize 
quickly resulting into a faster drug release, better dissolution 
and a noticeable therapeutic effect. This behavior is well 
supported by the acidic and ionic nature of vaginal milieu 
which adds to a higher dielectric constant of the medium.
On the other hand an HP-β-CD- Itz complex releases 
drug by a sheer mechanism which only involves diffusion 
based on the concentration gradient.
In vitro cell toxicity studies of complexes
The corresponding values for optical density for 
the control, neat drug and the complexes are shown in 
FIGURE 9- Outcome of vaginal infection by C. albicans in 
oophorectomized, estradiol-treated rats after infections with 108 
C. albicans cells. Each curve represents the mean (6 standard 
error) of the fungal CFU of six rats.
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Figure 10. Itz as a pure drug was found to have some cyto-
toxic effect. At the lowest concentration (50 µg/mL) relative 
difference of cell death was not distinguishable from each 
other, although none of them interfered with cell growth. 
However at higher concentrations (100 µg/mL, 200 µg/mL 
and 500 µg/mL) some conclusive results were obtained. HP-
β-CD and β-CD complexes showed some negative pattern 
in cell growth as compared to other complexing agents. 
However, for the complexes the toxicity did not increase at 
higher concentrations.Thus, the reports of in vitro cell toxic-
ity study did not indicate any serious cellular toxicity and the 
results are in agreement with earlier studies which reported 
humic substances to be safe according to the cytotoxicity 
studies (Yamada et al., 2007).
CONCLUSION
Itz-inclusion complexes have been successfully 
used to improve the performance of this poorly soluble 
drug. Fulvic acid, a naturally occurring substance, has 
displayed its suitability as a complexing agent which can 
successfully harness the potential of Itz as an antifungal 
agent. Its topical application in the form of a gel can be 
effectively used to ameliorate vaginal candidiasis, which 
is a recurrent problem in women of reproductive age. In 
an earlier communication we have shown the evaluation 
of a tablet constituting of Itz-FA. Fortunately, fulvic acid 
had elicited an adequate acid buffering and mucoadhesion 
properties, which strongly supports its use in the physi-
ologically variable pH milieu of the vaginal cavity. Con-
clusively, an Itz-FA inclusion complex offers a promise 
for development of a purported formulation for treatment 
of vaginal candidiasis.
FIGURE 10 - MTT assay results of pure drug and complexes. 
At lower concentrations all constituents were showing similar 
effect on cell growth. But the differences were evident at higher 
concentrations.
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